Shire (LON:SHP) has been given a consensus rating of “Buy” by the twenty-two brokerages that are currently covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation, fifteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is GBX 4,762.88 ($63.91).
A number of research analysts recently commented on SHP shares. JPMorgan Chase & Co. downgraded Shire to a “neutral” rating and reduced their price target for the company from GBX 5,000 ($67.09) to GBX 3,600 ($48.30) in a report on Tuesday, February 20th. Royal Bank of Canada reissued an “outperform” rating on shares of Shire in a report on Tuesday, April 17th. Kepler Capital Markets reissued a “buy” rating and issued a GBX 4,250 ($57.02) price target on shares of Shire in a report on Friday, April 27th. BNP Paribas reissued an “outperform” rating and issued a GBX 4,700 ($63.06) price target on shares of Shire in a report on Thursday, March 22nd. Finally, Morgan Stanley reduced their price target on Shire from GBX 5,700 ($76.48) to GBX 4,700 ($63.06) and set an “overweight” rating for the company in a report on Monday, March 19th.
Shares of Shire traded up GBX 30.50 ($0.41), hitting GBX 4,133.50 ($55.46), on Monday, according to Marketbeat.com. The company had a trading volume of 1,778,328 shares, compared to its average volume of 3,140,000. Shire has a 12-month low of GBX 2,940.50 ($39.45) and a 12-month high of GBX 5,021 ($67.37).
Shire Company Profile
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.